Background The adoption of oncology biosimilars has been slow in the USA, which may be
attributed in part to stakeholder perceptions and lack of operational guidance that supports …

73 Background: Biosimilar drugs, defined as biologic products with no clinically significant
differences in quality, efficacy and safety compared to approved reference products have …

Globally, biosimilars are expected to have a key role in improving patient access to
biological therapies and addressing concerns regarding the escalating cost of health care …

Biosimilar agents are biologic products that have been shown to be" highly similar" to an
already approved reference biologic product. Their integration into clinical practice has the …

Biosimilar monoclonal antibodies are being developed globally for patients with different
types of solid tumors and hematologic malignancies. Applications for proposed biosimilar …

Importance Biosimilars are biological medicines that contain a highly similar version of the
active substance of an already approved biologic reference product. The availability of …

Biological drugs are vital but often high-cost components of cancer treatment. Several
biosimilar versions of these drugs have been approved in Europe and/or the USA, with …

Background Biologic treatments for cancer continue to place a significant economic burden
on healthcare stakeholders. Biosimilar therapies may help reduce this burden through cost …

Background: Biosimilars provide opportunities for improving healthcare access and
outcomes and reducing overall healthcare costs for patients with cancer. Objectives: The …

The development of innovator biologics and now their biosimilars has created some unique
challenges in oncology practice. The oncology advanced practitioner (OAP) must …